Inducing Immune Control of Bacterial Virulence Regulation

诱导细菌毒力调节的免疫控制

基本信息

批准号：
9299851
负责人：
Pamela Ranel Hall
金额：
$ 22.45万
依托单位：
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-01-01 至 2018-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9299851
关键词：
Abscess Accident and Emergency department Address Adjuvant Affinity Alleles Alpha Particles Amino Acid Sequence Animal Model Antibiotic Resistance Antibiotics Antibodies Antigens Area Bacterial Infections Binding Body Weight decreased Buffers Cell membrane Centers for Disease Control and Prevention (U.S.)Chronic Granulomatous Disease Clinical Community-Acquired Infections Control Groups Data Development Diabetes Mellitus Disease Effectiveness Epitopes FDA approved Failure Female Genetic Transcription Goals Hospitals Human Human Papilloma Virus Vaccine Immune Immune Sera Immune response Immunity Immunize Immunologics Implant Individual Infection Inflammatory Response Job&apos s Syndrome Length Measurement Methicillin Resistance Modeling Monoclonal Antibodies Mus Operon Outcome Peptide Vaccines Peptides Population Prevalence Prevention Production Public Health Quantitative Reverse Transcriptase PCR Recurrence Regulation Regulator Genes Signal Transduction Site Skin Tissue Soft Tissue Infections Source Specificity Staphylococcus aureus Symbiosis Testing Translating United States National Institutes of Health Vaccination Vaccine Design Vaccines Virulence Virulence Factors Virus-like particle Western Blotting Work antimicrobial base combat design human disease immunogenicity improved outcome in vivo imaging innovation male methicillin resistant Staphylococcus aureus mouse model novel strategies novel vaccines pathogen peptide vaccination prevent protein expression protein-histidine kinase receptor subcutaneous vaccine development vaccine effectiveness vaccine efficacy virtual

项目摘要

PROJECT SUMMARY: Staphylococcus aureus (SA), including methicillin-resistant (MRSA), is the most common cause of skin and soft tissue infection (SSTI) in the US. To date, no vaccine to prevent SA infection has succeeded in human trials. Meanwhile, the need for a vaccine continues to escalate as does the ability of this pathogen to acquire antibiotic resistance. Our goal is to demonstrate the effectiveness of virus-like particles (VLPs) as an innovative platform to induce immune control of bacterial virulence regulation. VLPs are a novel approach to the design of vaccines targeting bacterial infection and the ability of VLP-based vaccines targeting SA virulence regulation has not been investigated. Therefore, the goal of this proposal is to test the hypothesis that presentation of SA virulence regulating peptides on VLPs can be used to induce protective immunity. Importantly, unlike other platforms and experimental adjuvants, VLPs are currently used in FDA- approved vaccines (like the current HPV vaccines). Therefore, if experimental approaches using VLPs are successful in animal models, they can potentially translate into human trials fairly readily.

项目摘要：金黄色葡萄球菌（SA），包括耐甲氧西林（MRSA），是最多的在美国，皮肤和软组织感染（SSTI）的常见原因。迄今为止，还没有防止SA感染的疫苗已经成功进行了人类试验。同时，对疫苗的需求继续升级这种获得抗生素耐药性的病原体。我们的目标是证明类似病毒的有效性颗粒（VLP）是一种创新平台，可诱导细菌毒力调节的免疫控制。 VLP是一种针对细菌感染的疫苗设计的新方法和基于VLP的疫苗的能力尚未研究靶向毒力调节。因此，该提议的目的是测试假设可以使用调节VLP上调节肽的Sa毒力来诱导保护性免疫。重要的是，与其他平台和实验佐剂不同，VLP当前用于FDA- 批准的疫苗（如当前的HPV疫苗）。因此，如果使用VLP的实验方法为在动物模型中成功，他们可以很容易地转化为人类试验。